Skip to content

Heather Rozjabek

2 papers in the library · 18 citations · publishing 2023

Papers

Sort Most recent Most cited

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Quality of Life Research November 2023 Carol Jamieson, Carla M. Canuso, Dawn F. Ionescu et al.

To assess the effect of esketamine nasal spray on patient-reported outcomes (PROs) in patients with major depressive disorder having active suicidal ideation with intent (MDSI). Patient-level data from two phase 3 studies (ASPIRE I; ASPIRE II) of esketamine + standard of care (SOC) in patients (aged 18-64 years) with MDSI, were pooled. PROs were evaluated from baseline through end of the...

DOI: 10.1007/s11136-023-03451-9 (opens in new tab) Full text (opens in new tab) Esketamine Major depressive disorder Patient-reported outcomes Pooled analysis +1

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

Health and Quality of Life Outcomes May 8, 2023 Carol Jamieson, Vanina Popova, Ella Daly et al. 18 citations

BACKGROUND: Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning. Esketamine effectively enhances the daily functioning in these patients while also improving their depressive symptoms. This study assessed HRQoL and health status of patients with TRD, who...

DOI: 10.1186/s12955-023-02113-1 (opens in new tab) Treatment-resistant depression Anxiety Depression economics Nasal spray +6